Myricetin and Naringenin Inhibit Human Squamous Cell Carcinoma Proliferation and Migration In Vitro

Abstract

In this study the potential anticancer effect of 2 flavonoids, myiricetin (MYR) and naringenin (NAR) has been evaluated on an oral squamous cell carcinoma (OSCC) cell line, SCC-25, and HaCaT cells. Both the flavonoids inhibited SCC-25 cell growth, although NAR selectively affected cancer cells without impairing HaCaT cell growth. The cell proliferation inhibition by MYR and NAR was not related to apoptosis induction, but on cell cycle impairment, because a G0/G1 and a G2/M blockage was highlighted following 24 h of treatment in SCC-25 and HaCaT cells, respectively. Western blot analysis showed that MYR induced a decrease of Cyclin D1 in SCC-25 and of Cyclin B1 in HaCaT cells, while NAR negatively modulated Cyclin D1 expression in SCC-25 cells. Wound-healing and cell invasion assays demonstrated that both the flavonoids were able to reduce motility on both SCC-25 and HaCaT cells. In conclusion the results of the present study show the anticancer potential of NAR and MYR on OSCC because they exert cytostatic effect by the impairment of cell cycle progression. Moreover both the flavonoids inhibit cell migration, thus highlighting their potential effect as antimetastatic agents. Therefore, MYR and NAR appear as promising candidate as oral cancer chemopreventive agents.

Inhibition of growth and migration of oral and cervical cancer cells by citrus polyphenol

“…29,30 Therefore, inhibition of the proliferation and migration of oral cancer cells is a very important topic.…”

Effects of flavonoids on tongue squamous cell carcinoma

“…Diosmin and hesperidin were not more when used in combination than when either was delivered alone, indicating that they do not act synergistically (Tanaka et al, 1997). (Li, Huang et al, 2013); 5 ; 6 (Li et al, 2010); 7 ; 8 (Ye et al, 2004); 9 (Lin et al, 2007); 10 ; 11 ; 12 (Lee et al, 2015); 13 ; 14 (Ji et al, 2018); 15 (Shih et al, 2017); 16 (Chou et al, 2018); 17 (Lai et al, 2013); 18 (Zhao et al, 2019); 19 ; 20 (Chen et al, 2012); 21 (Maggioni et al, 2014); 22 (Li et al, 2018); 23 (Gao et al, 2015); 24 (Tao et al, 2015); 25 (Tao et al, 2014); 26 (Babich et al, 2007); 27 (Pons-Fuster López et al, 2017); 28 (Mohan et al, 2007); 29 (Czyżewska et al, 2016); 30 (Yao et al,2005); 31 (Hua et al, 2006); 32 (Yang et al, 2017); 33 (Prasad & Katiyar, 2012); 34 ; 35 ; 36 (Hsia et al, 2016); 37 ; 38 (Nho et al, 2019); 39 (Cho et al, 2014); 40 ; 41 ; 42 (Chen et al, 2006); 43 (Won et al, 2018); 44 (Baba et al, 2015); 45 (Liu et al, 2016).…”

Myricetin inhibits panel of kinases implicated in tumorigenesis

“…This flavonoid presents several biological and therapeutic effects such as anti‐inflammatory, antioxidant and antitumour . Myricetin's ability to regulate cellular proliferation has been observed in several human cancer cell lines . However, myricetin exhibits no toxicity towards non‐tumorigenic cells …”

“…9,10 Myricetin's ability to regulate cellular proliferation has been observed in several human cancer cell lines. [11][12][13][14] However, myricetin exhibits no toxicity towards non-tumorigenic cells. 5,15 Protein kinases are involved in several cellular mechanisms, and, when activated, trigger pathways and processes of great biological importance.…”